Uterine fibroids : from observational epidemiology to clinical management by P. Vercellini & M.P. Frattaruolo
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/1471-0528.14730 
This article is protected by copyright. All rights reserved. 
Article Type: Mini-commentary 
 
Mini-commentary on 2016-SR-18387R1: Epidemiology of uterine fibroids: a systematic review 
 
Uterine fibroids: from observational epidemiology to clinical management 
 
Paolo VERCELLINI, M.D. 
Maria Pina FRATTARUOLO, M.D. 
 
Corresponding author mail id:-  paolo.vercellini@unimi.it 
 
From Fondazione Ca' Granda Ospedale Maggiore Policlinico and Department of Clinical Sciences and 
Community Health, Università degli Studi di Milano, Milan, Italy. 
 
The burden of uterine fibroids on women's health and national health systems' resources is worrying. 
Data are needed to further clarify the pathogenesis of these tumours and develop novel safe and cost-
effective treatments taking into account the factors that may influence their development and growth. 
In this regard, the findings of Stewart and co-workers (DOI:10.1111/1471-0528.14640) are important 
for women with uterine fibroids and healthcare providers.  
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 According to this systematic review of epidemiological studies, fibroid prevalence varied 
widely, with no consistent association across studies between observed estimates and country, 
methodology, and population. Fibroid incidence was higher in black than in white women 
independently of other risk factors, suggesting a racial predisposition. A genetic influence was 
confirmed also by the association with a positive family history. The association with age and 
menopausal status maybe interpreted in terms of varying degrees of oestrogen exposure, which could 
explain also the association with food additives and soybean consumption. Along this line, the "anti-
oestrogenic" effect of smoking was observed only in women with low BMI. Association were 
observed also with reproductive factors (parity and time since last birth) and oral/injectable 
contraceptives. 
  Predictably, selection, recall, and detection biases could not be excluded in the 60 cohort and 
case-control studies considered. Substantial qualitative heterogeneity prevented data pooling, limiting 
the translational value of this overview. Moreover, discriminating between symptomatic and 
asymptomatic lesions was unfeasible. This would have been relevant, as the authors report that 
fibroids occur in more than two thirds of women by the onset of menopause, but that only part of these 
tumours cause symptoms. The authors also state that the frequency of fibroids is likely to be 
underestimated because in many women they are asymptomatic and therefore remains undiagnosed. 
This would be important if all asymptomatic fibroids become symptomatic at some point in life, which 
is currently unproven. 
  Epidemiological data clarifying whether intramural/subserous fibroids were associated with 
infertility or unfavourable pregnancy outcomes would have been useful, as randomised, controlled 
trials on the effect of removal of fibroids that do not distort the uterine cavity are lacking. However, 
this would have needed categorisation of the number and dimension of tumours in addition to their 
location.  
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 Overall, Stewart and co-workers' results support the hypothesis that ethnic/genetic 
predisposition and ovarian hormones exposure are the main determinants of fibroid development. The 
former factor cannot be modified, whereas hormonal manipulation can be used to limit fibroid growth 
and alleviate menorrhagia and bulk symptoms. This explains the increasing interest in selective 
progesterone receptor modulators (SPRM) therapy as an alternative to invasive treatments. However, 
in published industry-sponsored clinical studies on long-term use of expensive SPRM, a comparison 
arm reflecting standard practice (myomectomy/hysterectomy) was not included. The combination of 
epidemiological and therapeutic uncertainties might here favour overdiagnosis, overtreatment, and 
low-value care. Publicly funded comparative effectiveness research measuring outcomes that matter to 
patients is now needed to assist women with fibroids and their physicians in making informed 
decisions in different clinical conditions. This could improve fibroid management enhancing health 
care quality, limiting health service overuse, and controlling costs.  
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